(Q36006401)

11 August 2017

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia (English)

1 reference

11 August 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

17

Kazuma Ohyashiki

1 reference

11 August 2017

7

Noriko Usui

1 reference

11 August 2017

Naoto Takahashi

1

1 reference

11 August 2017

Taiichi Kyo

2

1 reference

11 August 2017

Yasuhiro Maeda

3

1 reference

11 August 2017

Takashi Sugihara

4

1 reference

11 August 2017

Kensuke Usuki

5

1 reference

11 August 2017

Tatsuya Kawaguchi

6

1 reference

11 August 2017

Shinichiro Okamoto

8

1 reference

11 August 2017

Yokiko Ohe

9

1 reference

11 August 2017

Shigeki Ohtake

10

1 reference

11 August 2017

Kunio Kitamura

11

1 reference

11 August 2017

Masahide Yamamoto

12

1 reference

11 August 2017

Hirofumi Teshima

13

1 reference

11 August 2017

Toshiko Motoji

14

1 reference

11 August 2017

Toshiharu Tamaki

15

1 reference

11 August 2017

Kenichi Sawada

16

1 reference

11 August 2017

16 December 2011

1 reference

11 August 2017

1 reference

11 August 2017

97

1 reference

11 August 2017

6

1 reference

11 August 2017

903-906

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Discontinuation of imatinib therapy after achieving a molecular response

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3366657

Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22180435

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2011.056853

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22180435

1 reference